Our goal was to develop advanced high-throughput (HT) genetic screen technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs. Cellecta is headed by an experienced management and product development team with an excellent product development track record, a network of outside scientific collaborators, and prior experience in start-up company operations. Cellecta has partnered and published with renowned scientists and institutions, including the Roswell Park Cancer Institute, Fred Hutchinson Cancer Research Center (FHCRC), The Scripps Research Institute (TSRI), Harvard School of Public Health, Tufts University, and Health Research, Inc. Try Cellecta CRISPRa and CRISPRi Single- & Dual-sgRNA Libraries. We offer a variety of off-the-shelf products and custom services that enable:. Although a small private company, Cellecta is connected to a large network of collaborators, consultants, and colleagues, with a vast knowledge base in its research areas of expertise.
Mountain View, United States
Founded in 2006
11-50 Employees
Working industry
Biotechnology
Type of company
Manufacturer, Service provider
Ownership structure
Privately Held
Locations
1 Headquarter
Number of products
16 Products
Specialised areas
Scientific Research and Development Services, Professional, Scientific, and Technical Services, Custom CRISPR, shRNA, and cDNA Constructs, Cell-Tracking Lentiviral Barcode Libraries, Loss-of-Function Genetic Screens with Pooled Libraries, Biotechnical research, commercial, Health Care, Biotechnology, Custom Isogenic Cell Lines, Targeted Gene Expression Profiling
Cellecta offers a wide range of products and services
Product
Human Genome-Wide CRISPRi Dual-sgRNA Library | Cellecta, Inc - Cellecta
Go to product >
Product
NGS Prep Supplementary Primer Sets (12 Additional Index Primers for NGS Prep Kits) | Cellecta, Inc - Cellecta
Go to product >
Product
Custom Lentiviral cDNA Constructs - Cellecta
Go to product >
Product
Lentivirus Pseudotyping Service (e.g., Lentivirus with RFP reporter ps - Cellecta
Go to product >
Product
CRISPR sgRNA Lentiviral Vector with Tet-Inducible U6 Promoter (linearized, ready-for-cloning) | Cellecta, Inc - Cellecta
Go to product >
Product
NGS Prep Kit for Dual-sgRNA Libraries in pRSL10 (KADHGW/KIDHGW) | Cellecta, Inc - Cellecta
Go to product >
Product
Tet-Inducible GFP/RFP Reporter, Control to test Tet-inducible cell line (virus) | Cellecta, Inc - Cellecta
Go to product >
Product
CloneTracker™ XP-CRISPR Human 27 Anti-Cancer CRISPR-Barcode-3 Library - RFP-Puro | Cellecta, Inc - Cellecta
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Cellecta operates in 1 country around the world
Get an overview of the locations of Cellecta
Location
Country
State
City
Headquarter
United States
California
Mountain View
Some frequent questions that have been asked about Cellecta
Where is Cellecta located?
The company headquarter of Cellecta is located in Mountain View, California, United States. It's worth noting, that the company may have more locations
How many employees does Cellecta approximately have?
As of the latest available information Cellecta has around 11-50 employees worldwide.
When was Cellecta founded?
Cellecta was founded in 2006
In which industries does Cellecta mainly work?
The company Cellecta has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to Cellecta
Cellectis
Paris, France
51-100 Employees
1999
Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. Cellectis has 24 years of expertise in gene editing based on its flagship TALEN® technology and pioneering electroporation system PulseAgile. Cellectis is committed to good corporate governance, which promotes the long-term interests of shareholders, strengthens the Board of Directors and management accountability and helps build public trust in the Company. Cellectis is focused on addressing the medical and food needs of an ever-growing global population through the use of proprietary gene-editing technologies. Cellectis expects its associates, as well as its providers and subcontractors, to comply with this Charter in execution of their activities on a daily basis. Cellectis' gene edited CAR T-cells: how does it work? Cellectis leverages its leadership in gene editing through its flagship technology, TALEN®, which allows the company to create CAR T therapies to bring new hope to cancer patients through broadly available, off-the-shelf therapies. Cellectis gene-edits “Chimeric Antigen Receptor” (CAR) T-cells from healthy donors into “off-the-shelf” immunotherapy product candidates that are designed to work for the largest number of patients.
Cellected Limited
Salisbury, United Kingdom
1-10 Employees
-
Cellected was established to help iPSCs scientists with improving the quality and genetic integrity of the cell lines they work with on a day-to-day basis. As a team we are drawn to helping others with the challenges of iPSCs – and are proud of our novel RESCUE service. Cellected has developed a number of specialist services for iPSCs – including its acclaimed RIQUEST (for QC), RESCUE and SEED & GO services – which help clients comply rapidly and efficiently with the ISSCR standards re. We are only in the “foot hills” of iPSC science – but it is growing fast. Cellected has developed a range of specialist services for iPSCs which focus on in-process QC as well as improving the efficiency of iPSC research. Cellected’s service to ‘rescue’ iPSCs that show genomic abnormalities. Cellected is proposing a novel way to improve the quality of the iPSC assays – and reduce the time needed in the lab. Cellected has developed a specialist range of complementary services for iPSCs and other cell lines, as well as a number of support services designed to make clients research more efficient.
Myllia Biotechnology
Vienna, Austria
11-50 Employees
2018
Myllia has built an end-to-end genetic screening platform. At Myllia, we perform functional genomics at scale in advanced cellular models to map the impact of thousands of genetic perturbations at single-cell resolution – a new paradigm to nominate the best possible targets for your drug discovery campaign. We utilise the CROP-Seq (for “CRISPR Droplet Sequencing”) workflow, developed by Myllia´s co-founder Christoph Bock, to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next generation CRISPR screens. Tilmann is a CRISPR enthusiast since the early days of CRISPR. Tilmann is passionate about science and enjoys working with multi-disciplinary and multi-national teams. Christoph is a principal investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences. Their primary mission is to address critical challenges in deadly human cancers, particularly metastasis and drug resistance.
Celemics
Kazan, Russia
- Employees
2010
Introducing Celemics, your trusted partner for NGS solutions. Enabling highly efficient and cost-effective sequencing of your whole human exome with industry-leading coverage and uniformity. Innovative High Purification Efficiency Magnetic Bead for NGS Workflow. Experience the finest targeted sequencing solution with Celemics’ proprietary technologies. Experience the finest targeted sequencing solution with Celemics’ proprietary technologies. Complex genetic studies and developing new strategies for crop and animal productivity and sustainability. Highly optimized somatic cancer NGS panel with market-leading sensitivity and specificity. Identifying and characterizing the molecular fingerprint for tumor cell with Celemics’ comprehensive NGS solution.
Single Cell Discoveries
Utrecht, Netherlands
11-50 Employees
2018
We are focused on providing cutting-edge single-cell sequencing services to biopharmaceutical companies, health systems, and academic research centers globally. In alignment with our vision, we work on projects that help adapt single-cell applications to diagnostic and therapeutic purposes. We are the leading single-cell sequencing CRO providing high-impact insights to biopharmaceutical companies, health systems, and academic research centers globally. We are 100% focused on single-cell and spatial transcriptomics, enabling us to take on both large-scale projects and create customized solutions for each client project. We are committed to continuously integrating leading-edge technologies into our service offerings to ensure clients have access to the latest advancements. We are dedicated to maintaining a high-touch, collaborative relationship with clients as we scale our capacity to accommodate larger projects. What is now an industry-leading single-cell laboratory was once nothing more than a bold idea. The procedure was so laborious and the empty pipette boxes so numerous that Mauro committed himself to develop a higher-throughput, standardized protocol.
Berkeley Lights
Emeryville, United States
101-250 Employees
2011
Our unique suite of proven high-throughput tools and services offer unparalleled resolution and speed, accelerating the insights that are key to advancing discoveries that can profoundly improve the prevention and treatment of disease. Accelerate your product development by analyzing the phenotype and genotype of single cells or clones and generating insights by rapidly screening 1000s of cells at once.